HSP90AB1 and glioblastoma: As discussed above, Hsp90 and its client proteins have become validated as a novel drug target for GBM and other cancer treatments in both single and combination therapy since Hsp90 involves several molecular signalings of tumorigenesis, including apoptosis, proliferation, angiogenesis, migration, invasion, and metastasis.